ClinicalTrials.gg

Program

Anti-CD38 Monoclonal Antibody

Its studies are mostly in Multiple Myeloma, led by Chongqing Genrix Biopharmaceutical.

Furthest: phase 2, since Jul 21, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Genrix Biopharmaceutical11 open or runningphase 2since Jul 21, 2025Jul 21, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2025First study: phase 2 study in Multiple MyelomaFirst studyNCT07090954 · 32 planned · China

TargetBeta

CD38 →read by rule
“Any monoclonal antibody that is directed against the CD38 antigen.”NCIt, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07090954Multiple Myeloma · China2Not yet recruitingJul 31, 202632

How it is read

Names in the registry

  • “Anti-CD38 Monoclonal Antibody”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.